Responsibilities of the Marketing Authorisation Holders in Respect of GMP Compliance (Review)
Introduction. The article is focused on differences in quality assurance-related obligations and responsibilities between Marketing Authorisation Holders (MAHs) and manufacturing authorisation holder (manufacturers) in pharmaceutical industry. In case of outsourcing and technical agreements there is...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2020-11-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/821 |
| _version_ | 1797874945478361088 |
|---|---|
| author | A. P. Meshkovskiy N. V. Pyatigorskaya Z. I. Aladysheva V. V. Beregovykh A. M. Pyatigorskiy N. S. Nikolenko M. M. Marshalova V. V. Belyaev |
| author_facet | A. P. Meshkovskiy N. V. Pyatigorskaya Z. I. Aladysheva V. V. Beregovykh A. M. Pyatigorskiy N. S. Nikolenko M. M. Marshalova V. V. Belyaev |
| author_sort | A. P. Meshkovskiy |
| collection | DOAJ |
| description | Introduction. The article is focused on differences in quality assurance-related obligations and responsibilities between Marketing Authorisation Holders (MAHs) and manufacturing authorisation holder (manufacturers) in pharmaceutical industry. In case of outsourcing and technical agreements there is a need to differentiate responsibilities related to quality assurance between the above mentioned categories.Text. The guidelines for the pharmaceutical sector of the European Union (EU) provide guidance on the responsibilities of the MAHs in relation to the GMP rules, which are scattered throughout the various chapters of the GMP and its appendices. In addition, certain provisions on this topic are contained in the EU directives. With this in mind the European Medicines Agency (EMA) issued in January 2020 a draft Reflection paper on Good manufacturing practice and Marketing Authorisation Holders. The draft clarifies that while certain activities of an MAH may be delegated to the manufacturer, MAH retains ultimate responsibility for the performance of a medicinal product, its safety, quality and efficacy. The important obligation of MAH in this context is to facilitate GMP compliance by establishing a robust two-way communication system with national competent authorities, manufacturing sites, Qualified Persons (QPs) certifying batches before release, and other interested parties. The MAH ought to communicate to manufacturing personnel, normally through QPs, production processes and related quality control procedures, including subsequent variations, described in registration dossiers.Conclusion. A general one conclusion: in view of rapid developments in the EU GMP Guide, the Eurasian Economic Union GMP requirements ought to be updated. In respect of specific responsibilities of MAH pertaining to GMP compliance the EMA draft Reflection paper merits attention as a guidance regarding separation of obligations and responsibilities between MAH and personnel of manufacturing sights. |
| first_indexed | 2024-04-10T01:39:58Z |
| format | Article |
| id | doaj.art-2cfb3fb55f4c42ddabecd9cf63568154 |
| institution | Directory Open Access Journal |
| issn | 2305-2066 2658-5049 |
| language | Russian |
| last_indexed | 2024-04-10T01:39:58Z |
| publishDate | 2020-11-01 |
| publisher | LLC Center of Pharmaceutical Analytics (LLC «CPHA») |
| record_format | Article |
| series | Разработка и регистрация лекарственных средств |
| spelling | doaj.art-2cfb3fb55f4c42ddabecd9cf635681542023-03-13T09:14:01ZrusLLC Center of Pharmaceutical Analytics (LLC «CPHA»)Разработка и регистрация лекарственных средств2305-20662658-50492020-11-019416417010.33380/2305-2066-2020-9-4-164-170777Responsibilities of the Marketing Authorisation Holders in Respect of GMP Compliance (Review)A. P. Meshkovskiy0N. V. Pyatigorskaya1Z. I. Aladysheva2V. V. Beregovykh3A. M. Pyatigorskiy4N. S. Nikolenko5M. M. Marshalova6V. V. Belyaev7ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)Introduction. The article is focused on differences in quality assurance-related obligations and responsibilities between Marketing Authorisation Holders (MAHs) and manufacturing authorisation holder (manufacturers) in pharmaceutical industry. In case of outsourcing and technical agreements there is a need to differentiate responsibilities related to quality assurance between the above mentioned categories.Text. The guidelines for the pharmaceutical sector of the European Union (EU) provide guidance on the responsibilities of the MAHs in relation to the GMP rules, which are scattered throughout the various chapters of the GMP and its appendices. In addition, certain provisions on this topic are contained in the EU directives. With this in mind the European Medicines Agency (EMA) issued in January 2020 a draft Reflection paper on Good manufacturing practice and Marketing Authorisation Holders. The draft clarifies that while certain activities of an MAH may be delegated to the manufacturer, MAH retains ultimate responsibility for the performance of a medicinal product, its safety, quality and efficacy. The important obligation of MAH in this context is to facilitate GMP compliance by establishing a robust two-way communication system with national competent authorities, manufacturing sites, Qualified Persons (QPs) certifying batches before release, and other interested parties. The MAH ought to communicate to manufacturing personnel, normally through QPs, production processes and related quality control procedures, including subsequent variations, described in registration dossiers.Conclusion. A general one conclusion: in view of rapid developments in the EU GMP Guide, the Eurasian Economic Union GMP requirements ought to be updated. In respect of specific responsibilities of MAH pertaining to GMP compliance the EMA draft Reflection paper merits attention as a guidance regarding separation of obligations and responsibilities between MAH and personnel of manufacturing sights.https://www.pharmjournal.ru/jour/article/view/821надлежащая производственная практикаправила gmpлекарственные средствафармацевтическая промышленность |
| spellingShingle | A. P. Meshkovskiy N. V. Pyatigorskaya Z. I. Aladysheva V. V. Beregovykh A. M. Pyatigorskiy N. S. Nikolenko M. M. Marshalova V. V. Belyaev Responsibilities of the Marketing Authorisation Holders in Respect of GMP Compliance (Review) Разработка и регистрация лекарственных средств надлежащая производственная практика правила gmp лекарственные средства фармацевтическая промышленность |
| title | Responsibilities of the Marketing Authorisation Holders in Respect of GMP Compliance (Review) |
| title_full | Responsibilities of the Marketing Authorisation Holders in Respect of GMP Compliance (Review) |
| title_fullStr | Responsibilities of the Marketing Authorisation Holders in Respect of GMP Compliance (Review) |
| title_full_unstemmed | Responsibilities of the Marketing Authorisation Holders in Respect of GMP Compliance (Review) |
| title_short | Responsibilities of the Marketing Authorisation Holders in Respect of GMP Compliance (Review) |
| title_sort | responsibilities of the marketing authorisation holders in respect of gmp compliance review |
| topic | надлежащая производственная практика правила gmp лекарственные средства фармацевтическая промышленность |
| url | https://www.pharmjournal.ru/jour/article/view/821 |
| work_keys_str_mv | AT apmeshkovskiy responsibilitiesofthemarketingauthorisationholdersinrespectofgmpcompliancereview AT nvpyatigorskaya responsibilitiesofthemarketingauthorisationholdersinrespectofgmpcompliancereview AT zialadysheva responsibilitiesofthemarketingauthorisationholdersinrespectofgmpcompliancereview AT vvberegovykh responsibilitiesofthemarketingauthorisationholdersinrespectofgmpcompliancereview AT ampyatigorskiy responsibilitiesofthemarketingauthorisationholdersinrespectofgmpcompliancereview AT nsnikolenko responsibilitiesofthemarketingauthorisationholdersinrespectofgmpcompliancereview AT mmmarshalova responsibilitiesofthemarketingauthorisationholdersinrespectofgmpcompliancereview AT vvbelyaev responsibilitiesofthemarketingauthorisationholdersinrespectofgmpcompliancereview |